- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07801989
Alaska Alliance for Community Engagement Phase II: Partnership for Action Toward Health (AK ACE-PATH)
30 augustus 2026 bijgewerkt door: University of Alaska Fairbanks
Alaska Alliance for Community Engagement Phase II: Protecting Health in the American Arctic: Implementing Localized Solutions to Promote Health and Prevent Chronic Disease in Rural Alaska
The AK ACE-PATH Phase II study aims to pilot and implement a novel intervention, Tools for Arctic Health Promotion (TAHP), to address Alaska Native (AN) community priorities related to local health and community-level resilience.
Studie Overzicht
Toestand
Nog niet aan het werven
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
In Phase I of AK ACE, community partners identified and prioritized local stressors through a consensus-based process.
Building on these findings, Phase II will implement interventions targeting the highest-priority stressors through modules designed to improve health outcomes.This study addresses a critical gap in understanding local health and mental health among AN populations facing rapid social change and overlapping public health challenges.
The project focuses on developing community-driven solutions to improve physiological and mental health, particularly among youth, and to prevent chronic disease across the lifespan in rural Alaska.
To achieve these goals, the study will develop and implement Tools for Arctic Health Promotion (TAHP), a novel intervention integrating data-driven tools and evidence-based community strategies.
TAHP will support structured community engagement and deliver manualized health activities to approximately 410 adults and youth across five rural AN communities.
The TAHP intervention will be evaluated through a feasibility pilot in one community and a paired dynamic waitlisted design (DWLD) across four additional communities.
Behavioral and biological measures will assess individual- and community-level impacts on chronic disease prevention and mental health promotion.
Studietype
Ingrijpend
Inschrijving (Geschat)
360
Fase
- Fase 1
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studiecontact
- Naam: Stacy Rasmus, PhD
- Telefoonnummer: 907-328-8919
- E-mail: smrasmus@alaska.edu
Studie Contact Back-up
- Naam: Hannah Robinson, MPH
- Telefoonnummer: 731-400-3539
- E-mail: hrobinson3@alaska.edu
Studie Locaties
-
-
Alaska
-
Fairbanks, Alaska, Verenigde Staten, 99775
- University of Alaska Fairbanks
-
Contact:
- Maria Stejskal
- Telefoonnummer: 907-474-6230
- E-mail: mtrussell@alaska.edu
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Kind
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Ja
Beschrijving
Inclusion Criteria:
- Self-identify as a permanent resident of the study community
- Be a youth between the ages of 12-17 years or an adult 18+
- Be able to provide written informed consent
Exclusion Criteria:
- Does not have permanent residence in the community or has lived in the community less than 5 years
- Is unable to provide written informed consent
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Enrollment in TAHP
The study will enroll 360 participants from four unique community settings to receive the TAHP intervention.
The study design will make use of a dynamic wait-listed design (DWLD) with 360 participants assessed with behavioral and community-level measures at four time points: baseline (B), intervention midpoint (T1), Intervention end (T2) and 12-month follow-up (T3).
|
The TAHP intervention will utilize a valid measure of rural AN community-level protective factors (Allen, et al., 2025), and an evidence-based toolkit containing strategies proven to increase mental health and well-being in rural AN communities (Allen, Charles, et al., 2023).
A formalized community engaged process will generate new intervention activities that integrate cutting-edge science to address local health priorities.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Perceived Stress Scale Questionnaire will measure individual-level indicators of stress that we hypothesize will decrease over time with intervention participation
Tijdsspanne: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
The NIH Toolbox Perceived Stress Scale is a standardized tool designed to assess how unpredictable, uncontrollable, and overloaded individuals feel in their lives.
We will analyze how individual stress indicators are mitigated over time by intervention participation.
|
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
|
General Life Satisfaction Scale will measure individual level indicators of life satisfaction that we hypothesize will increase with intervention participation
Tijdsspanne: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
The NIH Toolbox General Life Satisfaction Scale is a tool designed to assess an individual's cognitive evaluation of their life experiences and overall satisfaction.
We will assess how the intervention mitigates life satisfaction with individuals who participate.
|
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
|
We will assess if depression decreases with intervention participation using the PHQ-9 Questionnaire
Tijdsspanne: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
The Patient Health Questionnaire 9 (PHQ-9) measures the frequency of depressed mood and anhedonia over the past two weeks.
We will assess how the intervention impacts depressive symptoms with individual participation.
|
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
|
We will assess if anxiety symptoms decrease with intervention participation using the GAD-7
Tijdsspanne: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
The Generalized Anxiety Disorder 7-Item (GAD-7) Screener will be given at every time point to assess how the intervention mitigates anxiety with individual participants
|
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
|
We will assess if food security increases using the food security index from the PhenX Toolkit
Tijdsspanne: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
The PhenX Toolkit includes standardized measures for assessing food security, which is crucial for understanding social determinants of health.
We will use items from the standardized food security tools to evaluate how food access impacts health outcomes and if food security increases with individual participation in the intervention.
|
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
|
We will assess if cultural efficacy increases with individual intervention participation using the Cultural Efficacy Scale.
Tijdsspanne: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
The Cultural Efficacy Scale developed by Gonzalez, Sittner, and Walls in 2022 measures individuals' comfort and access to cultural and traditional resources, particularly within Indigenous communities.
This scale consists of 7-8 items, each with a range of response options from "strongly disagree" to "strongly agree."
We will analyze the data to link cultural efficacy with mental health outcomes (depression and anxiety), highlighting the protective effects of engagement in the intervention.
|
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
|
We will assess how the intervention increases individual protective factors using the Multi-Cultural Mastery Scale
Tijdsspanne: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
The Multicultural Mastery Scale, developed by Allen and Mohatt, assesses coping strategies through self-mastery and communal mastery dimensions.
It includes subscales that differentiate between mastery related to family and friends, highlighting the importance of social networks.
We will utilize data from this scale to determine how the intervention increases positive coping and builds social networks connections in individuals who participate.
|
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
|
We will assess how intervention participation increases social and cultural connectedness using the Awareness of Connectedness Scale
Tijdsspanne: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
The Awareness of Connectedness Scale (ACS), developed by Mohatt and Fok, measures an individual's awareness of their interrelatedness with family, community, and the natural environment.
This scale is particularly focused on cultural aspects of wellness and healing among Alaska Native people, providing insights into their social and ecological connections.
We will utilize data from the scale to assess the intervention impacts on building connectedness among individual participants.
|
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
|
We will assess how the intervention increases reasons for life and meaning and purpose using the Reasons for Life Scale
Tijdsspanne: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
The Reasons for Life Scale (RFL), developed by Allen and Rasmus, focuses on cultural strengths and protective factors against suicide, particularly among Alaska Native people.
It emphasizes resilience, cultural teachings, and community recognition as vital components in promoting mental health and preventing suicide.
We will utilize data from scale to assess how the intervention promotes reasons for life and associates with mental health outcomes (depression and anxiety) in individuals who participate in activities.
|
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
We will assess the increase in community-level factors that are protective and contribute to health outcomes using the Protective Community Scale
Tijdsspanne: Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
The Protective Community Scale (PCS), developed by Wexler, Allen, and Rasmus, aims to identify community-level protective factors that can reduce suicide risk among Alaska Native youth.
This scale is part of a broader effort to enhance resilience in these communities through culturally relevant measures and community engagement.
We will analyze data from the PCS to determine if the intervention has mitigated environmental stressors and increased community protection.
|
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
We will assess changes to a stress biomarker, cortisol, using Salimetrics OnTimePoint SalivaTM Collection Management application system.
Tijdsspanne: Day 1 (baseline), 8 months (T2) and at 20 months (T3)
|
To measure the impacts of our intervention on biological outcomes, we will assess biomarkers associated with allostatic load - cortisol as an indicator of physiological stress response.
These biomarkers will allow us to evaluate whether participation in the intervention is associated with reduced chronic stress burden and improved mental health (anxiety and depression) over time.
Our proposed saliva collection protocol will involve our research team members administering the saliva kits with youth and adult participants over a 3-day period with multiple tests to capture cortisol levels throughout the day.
Multi-day cortisol levels will be averaged to determine a baseline, and the same process will be used for saliva collection and measurement of cortisol levels at each time point.
|
Day 1 (baseline), 8 months (T2) and at 20 months (T3)
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Publicaties en nuttige links
De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Geschat)
21 september 2026
Primaire voltooiing (Geschat)
31 oktober 2028
Studie voltooiing (Geschat)
30 april 2029
Studieregistratiedata
Eerst ingediend
25 augustus 2026
Eerst ingediend dat voldeed aan de QC-criteria
30 augustus 2026
Eerst geplaatst (Werkelijk)
3 september 2026
Updates van studierecords
Laatste update geplaatst (Werkelijk)
3 september 2026
Laatste update ingediend die voldeed aan QC-criteria
30 augustus 2026
Laatst geverifieerd
1 augustus 2026
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 6922-06-CH-S001
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
NEE
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .